But here's the hiccup on the imetelstat data revealed this morning, which I alluded to above: No clinical or symptomatic responses were reported, only bone marrow and blood response. The International Working Group (IWG) response criteria for myelofibrosis says a CR and a PR need to have bone marrow/blood response and clinical response, which usually means reduction in the size of the spleen.
Let the debate over Geron's myelofibrosis drug imetelstat rage on! We'll see updated results next month at the American Society of Hematology (AS) annual meeting.